Cyclooxygenases in the skin: pharmacological and toxicological implications

被引:152
作者
Lee, JL
Mukhtar, H
Bickers, DR
Kopelovich, L
Athar, M
机构
[1] Columbia Univ, Coll Phys & Surg, Dept Dermatol, New York, NY 10032 USA
[2] Univ Wisconsin, Sch Med, Madison, WI USA
[3] NCI, Div Canc Prevent, Bethesda, MD 20892 USA
关键词
D O I
10.1016/S0041-008X(03)00301-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cyclooxygenase (COX), a prostaglandin-endoperoxide synthase (PTGS), catalyzes the formation of prostaglandins from arachidonic acid. Prostaglandins are lipid signaling mediators that play a central role in a broad range of diverse physiological and pathophysiological processes, including inflammation, reproduction, nocioception, and gastrointestinal protection. Inhibition of cyclooxygenase activity is the mechanism by which nonsteroidal antiinflammatory drugs (NSAIDS) exert their analgesic, antipyretic, antiinflammatory, and antithrombotic effects. COX is currently believed to exist in three isoforms. In this review, we provide a concise state-of-the-art description of the role of COX in pharmacology and toxicology of skin including its involvement in normal physiology, cutaneous inflammation, nociception, wound healing, and tumorigenesis. COX-dependent pathways influence keratinocyte differentiation, hair follicle development, and hair growth. The critical role of COX-2 in pathophysiology of skin is also addressed. COX-2 mediates inflammatory processes in skin, including inflammatory hyperalgesia and nociception, and administration of specific COX-2 inhibitors reduces edema, vascular permeability, and other markers of cutaneous inflammation. A number of studies in animal models and in humans show that COX-2 inhibitors possess cancer chemopreventive properties. Selective COX-2 inhibitors have a more favorable side-effect profile. Topical formulations of COX-2 inhibitors are being developed as a novel pharmacologic approach for the treatment of COX-2 mediated skin diseases. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:294 / 306
页数:13
相关论文
共 120 条
[61]  
Müller-Decker K, 1998, MOL CARCINOGEN, V23, P36, DOI 10.1002/(SICI)1098-2744(199809)23:1<36::AID-MC5>3.0.CO
[62]  
2-F
[63]   Wound collagen deposition in rats:: effects of an NO-NSAID and a selective COX-2 inhibitor [J].
Muscará, MN ;
McKnight, W ;
Asfaha, S ;
Wallace, JL .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (04) :681-686
[64]  
Mutoh M, 2002, CANCER RES, V62, P28
[65]   Distribution and regulation of cyclooxygenase-2 in carrageenan-induced inflammation [J].
Nantel, F ;
Denis, D ;
Gordon, R ;
Northey, A ;
Cirino, M ;
Metters, KM ;
Chan, CC .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 128 (04) :853-859
[66]   Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin [J].
Neufang, G ;
Fürstenberger, G ;
Heidt, M ;
Marks, F ;
Müller-Decker, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (13) :7629-7634
[67]   Anti-inflammatory potency of FR167653, a p38 mitogen-activated protein kinase inhibitor, in mouse models of acute inflammation [J].
Nishikori, T ;
Irie, K ;
Suganuma, T ;
Ozaki, M ;
Yoshioka, T .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 451 (03) :327-333
[68]   INFLUENCE OF DIETARY MENHADEN OIL UPON CARCINOGENESIS AND VARIOUS CUTANEOUS RESPONSES TO ULTRAVIOLET-RADIATION [J].
ORENGO, IF ;
BLACK, HS ;
KETTLER, AH ;
WOLF, JE .
PHOTOCHEMISTRY AND PHOTOBIOLOGY, 1989, 49 (01) :71-77
[69]   Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer - A study in the hairless mouse model [J].
Orengo, IF ;
Gerguis, J ;
Phillips, R ;
Guevara, A ;
Lewis, AT ;
Black, HS .
ARCHIVES OF DERMATOLOGY, 2002, 138 (06) :751-755
[70]   INFLUENCE OF FISH OIL SUPPLEMENTATION ON THE MINIMAL ERYTHEMA DOSE IN HUMANS [J].
ORENGO, IF ;
BLACK, HS ;
WOLF, JE .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 1992, 284 (04) :219-221